Curated News
By: NewsRamp Editorial Staff
September 22, 2026
Nutriband Confirms Warrant Expiration: $5.86M Potential Proceeds
TLDR
- Nutriband warrants can be exercised at $6.43 until September 30, 2026, potentially raising $5.86 million for the company.
- Nutriband's 910,904 outstanding warrants expire September 30, 2026, at 5 p.m. EDT, with no extension or repricing allowed.
- Nutriband develops abuse-deterrent fentanyl patches to prevent misuse and accidental exposure, improving patient safety and public health.
- Nutriband's AVERSA technology can be added to any transdermal patch to deter abuse of drugs with abuse potential.
Impact - Why it Matters
The confirmation of Nutriband's warrant expiration without extension or repricing signals the company's confidence in its current valuation and future prospects. Warrant holders face a clear deadline to exercise their warrants at $6.43 per share, potentially injecting up to $5.86 million into the company. This capital could accelerate the development of Nutriband's lead product, an abuse-deterrent fentanyl patch using its AVERSA(TM) technology, which addresses the critical public health issue of opioid abuse. For investors, this news underscores the importance of timely action to avoid losing the opportunity to participate in Nutriband's growth. The announcement also highlights the role of NetworkNewsWire and IBN in disseminating crucial financial information, ensuring transparency and accessibility for the investment community.
Summary
Nutriband (NASDAQ: NTRB) has confirmed that its outstanding warrants will expire as scheduled on Sept. 30, 2026, at 5 p.m. EDT, with no extension or repricing. Warrant holders may exercise at the current strike price of $6.43 per share until expiration, after which unexercised warrants will expire in their entirety and be removed from the NTRBW Nasdaq listing. The company currently has 910,904 warrants outstanding, representing approximately $5.86 million in potential proceeds if all warrants are exercised at the $6.43 strike price. This firm stance on the warrant terms reflects Nutriband's confidence in its financial position and strategic direction.
Nutriband is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Its lead product under development is an abuse-deterrent fentanyl patch incorporating its AVERSA(TM) abuse-deterrent technology. AVERSA(TM) technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. The company's innovative approach addresses a critical public health issue, positioning it as a key player in the pharmaceutical industry. For more information, visit the company's website at www.nutriband.com.
The announcement was distributed through NetworkNewsWire ('NNW'), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. NNW is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and corporate communications solutions. This broad reach ensures that Nutriband's news is effectively disseminated to investors and the public.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Nutriband Confirms Warrant Expiration: $5.86M Potential Proceeds
